⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TNXP News
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026
globenewswire.com
TNXP
Form 8-K
sec.gov
TNXP
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain
globenewswire.com
TNXP
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
globenewswire.com
TNXP
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
globenewswire.com
TNXP
Form 8-K
sec.gov
TNXP
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
globenewswire.com
TNXP
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
globenewswire.com
JUNS
DYAI
PHIO
CVKD
TNXP
MTVA
XAIR
AEMD
NSRX
ICU
JAGX
Form 8-K
sec.gov
TNXP
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
globenewswire.com
TNXP